NCT05935033View on ClinicalTrials.gov

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

PHASE1CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

February 21, 2025

Study Completion Date

February 21, 2025

Conditions

Hepatic Impairment

Interventions

DRUG

Emraclidine

Tablet

Trial Locations (3)

32809

Orlando, Florida, Orlando

33136

Miami, Florida, Miami

78215

San Antonio, Texas, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AbbVie

INDUSTRY